On March 6, 2026, Solid Biosciences Inc. entered into a securities purchase agreement to raise approximately $240 million by selling about 14.97 million shares of common stock at $5.61 per share and pre-funded warrants, expected to close around March 9, 2026. This funding aims to support ongoing development and operational expenses, with an estimated cash position of $187.9 million as of December 31, 2025.